Intrinsic Value of S&P & Nasdaq Contact Us

Centene Corporation CNC NYSE

NYSE • Healthcare • Medical - Healthcare Plans • US • USD

SharesGrow Score
55/100
1/7 Pass
SharesGrow Intrinsic Value
$1,904.59
+5013%
Analyst Price Target
$44.90
+20.5%
SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Centene Corporation (CNC) has a negative trailing P/E of -2.7, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 12.5 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -36.40%, forward earnings yield 8.03%. PEG 0.38 (Peter Lynch undervalued ≤1.0).

Criteria proven by this page:

  • VALUE (86/100, Pass) — PEG ≤ 1.0 — Peter Lynch undervalued (0.38); analyst target implies upside (+20.5%).
  • Forward P/E 12.5 — analysts expect a return to profitability with estimated EPS of $2.99 for FY2026.
  • PEG Ratio 0.38 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
  • Trailing Earnings Yield -36.40% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 8.03% as earnings recover.
  • Analyst consensus target $44.90 (+20.5% upside) — significant upside potential according to Wall Street analysts.

Overall SharesGrow Score: 55/100 with 1/7 criteria passed.

SharesGrow 7-Criteria Score
55/100
SG Score
View full scorecard →
VALUE
86/100
Price-to-Earnings & upside
Proven by this page
~
FUTURE
58/100
Analyst consensus
→ Forecast
~
PAST
75/100
→ Income
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
~
MOAT
56/100
→ Income
~
GROWTH
48/100
→ Income
INCOME
10/100
→ Income

Valuation Snapshot — CNC

Valuation Multiples
P/E (TTM)-2.7
Forward P/E12.5
PEG Ratio0.38
Forward PEG0.38
P/B Ratio0.92
P/S Ratio0.09
EV/EBITDA-3.7
Per Share Data
EPS (TTM)$-13.59
Forward EPS (Est.)$2.99
Book Value / Share$40.84
Revenue / Share$396.64
FCF / Share$8.80
Yields & Fair Value
Earnings Yield-36.40%
Forward Earnings Yield8.03%
Dividend Yield0.00%
SharesGrow IV$1,904.59 (+5013%)
Analyst Target$44.90 (+20.5%)

Historical Valuation

Year P/E (TTM) PEG Ratio P/B Ratio P/S Ratio Dividend Yield
2016 16.0 0.89 1.53 0.22 -
2017 21.0 0.58 2.54 0.36 -
2018 25.0 -6.67 2.06 0.37 -
2019 19.7 0.52 2.07 0.35 -
2020 18.9 -30.22 1.33 0.31 -
2021 35.7 -1.31 1.79 0.38 -
2022 39.2 -4.12 1.96 0.33 -
2023 14.9 0.11 1.56 0.26 -
2024 9.6 0.35 1.20 0.19 -
2025 -3.0 0.01 1.01 0.10 -

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year EPS (Diluted) Revenue Net Income Net Margin
2016 $1.72 $40.61B $562M 1.4%
2017 $2.35 $48.38B $828M 1.7%
2018 $2.26 $60.12B $900M 1.5%
2019 $3.14 $74.64B $1.32B 1.8%
2020 $3.12 $111.12B $1.81B 1.6%
2021 $2.28 $125.98B $1.35B 1.1%
2022 $2.07 $144.55B $1.2B 0.8%
2023 $4.95 $154B $2.7B 1.8%
2024 $6.31 $163.07B $3.31B 2%
2025 $-13.62 $194.78B $-6.67B -3.4%

Analyst Estimates

Year EPS (Avg) EPS Range Revenue (Avg) Revenue Range Analysts
2026 $2.98 $2.76 – $3.58 $189.8B $186.87B – $192.46B 12
2027 $4.01 $3.31 – $4.90 $189.95B $181.75B – $197.8B 12
2028 $5.61 $5.29 – $6.01 $195.76B $195.49B – $196.02B 3
2029 $8.23 $7.90 – $8.53 $196.32B $190.26B – $201.91B 1
2030 $8.79 $8.44 – $9.12 $200.38B $194.18B – $206.08B 1
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message